Company
Headquarters: Beijing, China
Employees: 952
CN¥16.25 Billion
CNY as of Jan. 1, 2026
US$2.32 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers drug detection, CDC, Up-conversion luminescence technology, colloidal gold, CLIA, sugar capture, microfluidic, and gene detection products for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. The company was founded in 2005 and is based in Beijing, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥434.4 M |
| EBITDA | CN¥-107,050,296 |
| Gross Profit TTM | CN¥221.7 M |
| Profit Margin | -59.69% |
| Operating Margin | -40.36% |
| Quarterly Revenue Growth | -23.00% |
Beijing Hotgen Biotech Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688068 wb_incandescent